申请人:Cancer Research Technology Limited
公开号:US07105518B2
公开(公告)日:2006-09-12
The present invention provides compounds of formula (I) and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, wherein R1 and R2 are independently hydrogen, an option ally substituted C1-7 alkyl group, C3-20 heterocyclyl group, or C5-20 aryl group, or may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; and R3 is an optionally substituted C3-20 heterocyclyl or C5-20 aryl group, and their use as pharmaceuticals, particularly in treating diseases which are retroviral mediated or ameliorated by the inhibition of DNA-PK,
本发明提供了式(I)及其异构体,盐,溶剂合物,化学保护形式和前药的化合物,其中R1和R2分别为氢,可选择性取代的C1-7烷基,C3-20杂环基或C5-20芳基,或者可以与它们附着的氮原子一起形成具有4至8个环原子的可选择性取代的杂环环;而R3是可选择性取代的C3-20杂环或C5-20芳基,以及它们作为药物的用途,特别是用于治疗由逆转录病毒介导或通过抑制DNA-PK改善的疾病。